These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 15000491)

  • 1. A clue to the therapy of neurofibromatosis type 2: NF2/merlin is a PAK1 inhibitor.
    Hirokawa Y; Tikoo A; Huynh J; Utermark T; Hanemann CO; Giovannini M; Xiao GH; Testa JR; Wood J; Maruta H
    Cancer J; 2004; 10(1):20-6. PubMed ID: 15000491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Merlin, the product of the Nf2 tumor suppressor gene, is an inhibitor of the p21-activated kinase, Pak1.
    Kissil JL; Wilker EW; Johnson KC; Eckman MS; Yaffe MB; Jacks T
    Mol Cell; 2003 Oct; 12(4):841-9. PubMed ID: 14580336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation of the p21-activated kinases as targets for inhibition in neurofibromatosis type 2.
    Yi C; Wilker EW; Yaffe MB; Stemmer-Rachamimov A; Kissil JL
    Cancer Res; 2008 Oct; 68(19):7932-7. PubMed ID: 18829550
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kinase-deficient Pak1 mutants inhibit Ras transformation of Rat-1 fibroblasts.
    Tang Y; Chen Z; Ambrose D; Liu J; Gibbs JB; Chernoff J; Field J
    Mol Cell Biol; 1997 Aug; 17(8):4454-64. PubMed ID: 9234703
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FRAX597, a small molecule inhibitor of the p21-activated kinases, inhibits tumorigenesis of neurofibromatosis type 2 (NF2)-associated Schwannomas.
    Licciulli S; Maksimoska J; Zhou C; Troutman S; Kota S; Liu Q; Duron S; Campbell D; Chernoff J; Field J; Marmorstein R; Kissil JL
    J Biol Chem; 2013 Oct; 288(40):29105-14. PubMed ID: 23960073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CAPE (caffeic acid phenethyl ester)-based propolis extract (Bio 30) suppresses the growth of human neurofibromatosis (NF) tumor xenografts in mice.
    Demestre M; Messerli SM; Celli N; Shahhossini M; Kluwe L; Mautner V; Maruta H
    Phytother Res; 2009 Feb; 23(2):226-30. PubMed ID: 18726924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PAK1 inhibition reduces tumor size and extends the lifespan of mice in a genetically engineered mouse model of Neurofibromatosis Type 2 (NF2).
    Hawley E; Gehlhausen J; Karchugina S; Chow HY; Araiza-Olivera D; Radu M; Smith A; Burks C; Jiang L; Li X; Bessler W; Masters A; Edwards D; Burgin C; Jones D; Yates C; Clapp DW; Chernoff J; Park SJ
    Hum Mol Genet; 2021 Aug; 30(17):1607-1617. PubMed ID: 34075397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. p21-activated kinase links Rac/Cdc42 signaling to merlin.
    Xiao GH; Beeser A; Chernoff J; Testa JR
    J Biol Chem; 2002 Jan; 277(2):883-6. PubMed ID: 11719502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The scaffold protein KSR1, a novel therapeutic target for the treatment of Merlin-deficient tumors.
    Zhou L; Lyons-Rimmer J; Ammoun S; Müller J; Lasonder E; Sharma V; Ercolano E; Hilton D; Taiwo I; Barczyk M; Hanemann CO
    Oncogene; 2016 Jun; 35(26):3443-53. PubMed ID: 26549023
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Missense mutations in the NF2 gene result in the quantitative loss of merlin protein and minimally affect protein intrinsic function.
    Yang C; Asthagiri AR; Iyer RR; Lu J; Xu DS; Ksendzovsky A; Brady RO; Zhuang Z; Lonser RR
    Proc Natl Acad Sci U S A; 2011 Mar; 108(12):4980-5. PubMed ID: 21383154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LIM domain kinases as potential therapeutic targets for neurofibromatosis type 2.
    Petrilli A; Copik A; Posadas M; Chang LS; Welling DB; Giovannini M; Fernández-Valle C
    Oncogene; 2014 Jul; 33(27):3571-82. PubMed ID: 23934191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. β1 integrin-dependent Rac/group I PAK signaling mediates YAP activation of Yes-associated protein 1 (YAP1) via NF2/merlin.
    Sabra H; Brunner M; Mandati V; Wehrle-Haller B; Lallemand D; Ribba AS; Chevalier G; Guardiola P; Block MR; Bouvard D
    J Biol Chem; 2017 Nov; 292(47):19179-19197. PubMed ID: 28972170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neurofibromatosis 2.
    Baser ME; R Evans DG; Gutmann DH
    Curr Opin Neurol; 2003 Feb; 16(1):27-33. PubMed ID: 12544854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NF2 Loss Promotes Oncogenic RAS-Induced Thyroid Cancers via YAP-Dependent Transactivation of RAS Proteins and Sensitizes Them to MEK Inhibition.
    Garcia-Rendueles ME; Ricarte-Filho JC; Untch BR; Landa I; Knauf JA; Voza F; Smith VE; Ganly I; Taylor BS; Persaud Y; Oler G; Fang Y; Jhanwar SC; Viale A; Heguy A; Huberman KH; Giancotti F; Ghossein R; Fagin JA
    Cancer Discov; 2015 Nov; 5(11):1178-93. PubMed ID: 26359368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NF2: the wizardry of merlin.
    Xiao GH; Chernoff J; Testa JR
    Genes Chromosomes Cancer; 2003 Dec; 38(4):389-99. PubMed ID: 14566860
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic effect of PAK and Hippo pathway inhibitor combination in NF2-deficient Schwannoma.
    Benton D; Yee Chow H; Karchugina S; Chernoff J
    PLoS One; 2024; 19(7):e0305121. PubMed ID: 39083549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional analysis of the relationship between the neurofibromatosis 2 tumor suppressor and its binding partner, hepatocyte growth factor-regulated tyrosine kinase substrate.
    Sun CX; Haipek C; Scoles DR; Pulst SM; Giovannini M; Komada M; Gutmann DH
    Hum Mol Genet; 2002 Dec; 11(25):3167-78. PubMed ID: 12444101
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The NF2 tumor suppressor gene product, merlin, inhibits cell proliferation and cell cycle progression by repressing cyclin D1 expression.
    Xiao GH; Gallagher R; Shetler J; Skele K; Altomare DA; Pestell RG; Jhanwar S; Testa JR
    Mol Cell Biol; 2005 Mar; 25(6):2384-94. PubMed ID: 15743831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Merlin, a regulator of Hippo signaling, regulates Wnt/β-catenin signaling.
    Kim S; Jho EH
    BMB Rep; 2016 Jul; 49(7):357-8. PubMed ID: 27345717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The genetic and molecular pathogenesis of NF1 and NF2.
    Yohay KH
    Semin Pediatr Neurol; 2006 Mar; 13(1):21-6. PubMed ID: 16818172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.